<DOC>
	<DOC>NCT01351688</DOC>
	<brief_summary>The primary aim of study is to gain an initial assessment of safety and tolerability of AZD3514 in Japanese patients together with assessing Pharmacokinetics (PK) and gaining a preliminary assessment of anti-tumour action. In this study, AZD3514 will be administered to Japanese patients with metastatic castration resistant prostate cancer.</brief_summary>
	<brief_title>An Open Label Prostate Cancer Study in Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males aged 20 years or older. Histologically or Cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate Documented evidence of metastatic prostate cancer Serum testosterone concentration â‰¤50 ng/dL World Health Organisation (WHO) performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks History of hypersensitivity to active or inactive excipients of AZD3514 or drugs with a similar chemical structure or class to AZD3514 Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD3514 Inadequate bone marrow reserve or organ function Concurrent or recent treatment with certain medications or medical procedures Any medically important factors identified from electrocardiogram (ECG) measurements</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castration resistant</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Androgen receptor</keyword>
	<keyword>Down regulation</keyword>
	<keyword>Japanese</keyword>
</DOC>